Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of AER 002 on mucociliary clearance in COPD
2005-005044-40Phase 2Completed
- Sponsor
- Aerovance
- Start
- Jan 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of AER002 in chronic obstructive pulmonary disease (COPD), sponsored by Aerovance. Primary endpoint: Mucociliary clearance rate. Started Jan 2006; status: completed.
02
Drugs
AER002
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2005-005044-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005044-40.